Navigation Links
Molecular network influences development of chronic lymphocytic leukemia
Date:1/25/2011

COLUMBUS, Ohio A study shows for the first time that the three most common chromosome changes seen in chronic lymphocytic leukemia disrupt a molecular network that includes several important genes and strongly influences the outcome of the disease.

The research was led by investigators at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at University of Texas M.D. Anderson Cancer Center, working in collaboration with investigators at seven other centers in Italy and the United States. The findings were published recently in the Journal of the American Medical Association (JAMA).

The network involves genes on chromosome 13, chromosome 11 and chromosome 17, along with the important tumor-suppressor gene TP53, the prognostically important molecule called ZAP-70 and two sets of regulatory molecules called microRNA.

"Our findings might allow doctors to better identify which CLL patients need closer follow-up or earlier treatment," says first author Dr. Muller Fabbri, a research scientist at the OSUCCC James. "Moreover, our study provides important new information about how CLL develops and identifies new molecular targets for the development of new treatments."

CLL is the most common leukemia in the U.S., where 15,000 new cases were expected in 2010, along with 4,400 deaths from the disease.

The disease has an extremely variable clinical outcome, Fabbri notes. While most patients have a slowly progressing form of the disease that requires little or no treatment for many years, others have aggressive disease that requires immediate therapy.

Chromosome damage is common in CLL, and it often involves the loss of pieces of chromosome 13. The loss of pieces of chromosomes 11 and 17 may also occur. More specifically, these changes are called the 13q deletion, and the 11q and 17p deletions.

"Patients with a 13q deletion generally have a better prognosis than patients with the 11q or 17p deletion," Muller says. "But we don't know why the loss of part of chromosome 13 results in a better prognosis. Our discovery helps unravel this mystery. It identifies a molecular mechanism that explains why these deletions affect patient outcome."

This study, led by Dr. Carlo M. Croce, professor of molecular virology, immunology and medical genetics, and director of the Human Cancer Genetics program at the OSUCCC James, shows that loss of chromosome 13q interrupts a biochemical network that involves two families of microRNA and the TP53 tumor-suppressor gene. The interruption leads to greater activity of two genes (BCL2 and MCL1), which prevents cancer cells from dying when they should, and to less activity by a gene called ZAP70. Low levels of ZAP70 are associated with milder disease, while high levels are associated with aggressive disease.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related biology news :

1. Polymer membranes with molecular-sized channels that assemble themselves
2. Molecular medicine could avert predicted catastrophic vision loss in the aged
3. New book highlights the cellular and molecular determinants of brain wiring
4. Scientists discover molecular switch that contributes to cellular aging process
5. Molecular fossil
6. Association for Molecular Pathologys 16th Annual Meeting and Exhibits
7. Understanding diabetes at the molecular level
8. Rictor protein offers scientists a new molecular target for cancer therapies
9. Penn study identifies molecular guardian of cells RNA
10. Bacteria gauge cold with molecular measuring stick
11. NIH funds Center of Excellence for Molecular Hematology at Cincinnati Childrens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics ... Center, Subha Madhavan , Ph.D., will be speaking ... Summits Panels. On Monday, March 27, 2017, she will ... Data More Usable for Research and Care" (from 10:30 ... 28, 2017, she will be a participant in the ...
(Date:3/27/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it is now offering ... U.S. consumers who want to have their DarioHealth products ... strategic alliance agreements with partners across the U.S. who ... if approved, will supply and bill the customer,s insurance ...
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" ... in China , today announced that its board ... expiration date of the plan from March 27, 2017 to March ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building ... challenges for companies around the world, such as Illumina, HP and Qualcomm, and is ranked ... its increasing popularity is due to its new team building format, a way for teams ...
Breaking Biology Technology: